Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FEC-100 Neoadjuvant Chemotherapy in Breast Cancer
NCT03696004Phase 3Unknown
- Sponsor
- Assiut University
- Start
- Dec 2018
- Primary completion
- Jun 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, open-label trial of fluorouracil, epirubicin and cyclophosphamide in breast cancer, sponsored by Assiut University. Primary endpoint: Tumour size measurement at 18 weeks. Status: unknown.
02
Drugs
fluorouracilepirubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03696004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03696004.